Cargando…

A Single Institution’s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma

BACKGROUND: Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly in regards to hemorrhage and thromboembolism. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayer, Tina, Lacy, Jill, Baehring, Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161684/ https://www.ncbi.nlm.nih.gov/pubmed/21892317

Ejemplares similares

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Disease progression patterns of bevacizumab responders with recurrent malignant gliomas
por: Kim, Ju-Hwi, et al.
Publicado: (2017)

Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low‐grade glioma
por: Zhukova, Nataliya, et al.
Publicado: (2018)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012)

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
por: Tao, Hong, et al.
Publicado: (2018)

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
por: Cha, Yongjun, et al.
Publicado: (2017)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

COT-22 TIMING OF SURGERY AND BEVACIZUMAB THERAPY FOR MALIGNANT GLIOMAS
por: Matsubara, Toshio, et al.
Publicado: (2019)

Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis
por: Hattori, Yasuhiko, et al.
Publicado: (2022)

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
por: Thomas, Alissa, et al.
Publicado: (2018)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial
por: Takano, Shingo, et al.
Publicado: (2014)

Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma
por: Calò, Pierluigi, et al.
Publicado: (2023)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas – A Pilot Study
por: SHIBA, Hiroyuki, et al.
Publicado: (2018)

Cytotoxicity induced by carbon nanotubes in experimental malignant glioma
por: Romano-Feinholz, Samuel, et al.
Publicado: (2017)

Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
por: Niyazi, Maximilian, et al.
Publicado: (2014)

Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series
por: Gaughan, Elizabeth M., et al.
Publicado: (2022)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study
por: Motoo, Nagane, et al.
Publicado: (2019)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients
por: Ueda, Shigeto, et al.
Publicado: (2014)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

Managing Side Effects of Cytotoxic Chemotherapy in Patients With High Grade Gliomas
por: Ha, Hyerim, et al.
Publicado: (2022)

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials
por: Chen, Zhouqing, et al.
Publicado: (2018)

ACT-09 RETROSPECTIVE INVESTIGATION ABOUT STATUS AND RESULT OF ADMINISTRATION OF BEVACIZUMAB FOR MALIGNANT GLIOMAS IN THE REAL WORLD
por: Hashiba, Tetsuo, et al.
Publicado: (2019)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
por: Blesa, Joan Manel Gasent, et al.
Publicado: (2012)

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients
por: Liu, Vicki, et al.
Publicado: (2023)

Reduction of End‐stage Malignant Glioma by Injection with Autologous Cytotoxic T Lymphocytes
por: Tsurushima, Hideo, et al.
Publicado: (1999)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
por: Wang, Min, et al.
Publicado: (2022)

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
por: Ahluwalia, Manmeet S., et al.
Publicado: (2010)

Vasorin stimulates malignant progression and angiogenesis in glioma
por: Liang, Weiye, et al.
Publicado: (2019)

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014)

Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials
por: Yang, Shou-Bo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eqbg5ahi3l21p10dkapd23mtgg